Helmholtz Munich partners with Medigene to accelerate Tumor Therapy
Helmholtz Munich and Medigene AG expand their partnership in order to further discover and develop T-cell immunotherapies for solid tumors. Medigene acquired from Helmholtz Munich the exclusive, worldwide rights to the CD40L-CD28 Costimulatory Switch…
Targeting Brain Tumors: New Drug Candidate in Clinical Trial
Clinical trials are a milestone in the development of safe and effective drugs and therapies. An antibody developed by Helmholtz Munich is now entering a phase 1 clinical trial. Together with the radiopharmaceutical company ITM Isotope Technologies…
"A startup can be just as big a success as a Leibniz Prize!"
Matthias Tschöp, CEO of Helmholtz Munich, talks about translating scientific discoveries into clinical practice, about ambitious targets, and about ideas he acquired during his time in the USA.
